Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • M&A / Deals
  • SonoThera bags $125M series B to advance safer gene therapies
  • M&A / Deals

SonoThera bags $125M series B to advance safer gene therapies

BioSpace

Instead of using viral vectors, SonoThera's genetic medicines are delivered through an ultrasound-mediated technology that could help sidestep key safety issues with conventional delivery methods.

Gene Therapy Platform

Read full story

pharminent June 11, 2026 (Last updated: June 15, 2026)

BioSpace

Instead of using viral vectors, SonoThera’s genetic medicines are delivered through an ultrasound-mediated technology that could help sidestep key safety issues with conventional delivery methods.

Gene Therapy Platform

Read full story

Post navigation

Previous: Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
Next: Novartis gets win for another Avidity muscular dystrophy AOC

Related Stories

  • M&A / Deals

Solstice Oncology secures $225m to drive porustobart’s development for cancer

pharminent September 10, 2026
  • M&A / Deals

UK’s Claret Capital raises 575m for European biotechs

pharminent September 7, 2026
  • M&A / Deals

GSK wagers up to $1.3B on a different kind of cancer drug

pharminent September 3, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.